Review
Gastroenterology & Hepatology
Sakura Yamamura, Dan Nakano, Ryuki Hashida, Tsubasa Tsutsumi, Takumi Kawaguchi, Michiaki Okada, Hiroshi Isoda, Hirokazu Takahashi, Hiroo Matsuse, Yuichiro Eguchi, Yoshio Sumida, Atsushi Nakajima, Lynn Gerber, Zobair M. Younossi, Takuji Torimura
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide and it is important to assess all associated outcomes including patient-reported outcomes (PROs). The Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH is a specific instrument developed for this purpose and has shown excellent reliability and validity in international clinical trials.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Nutrition & Dietetics
Gabriele Castelnuovo, Nuria Perez-Diaz-del-Campo, Chiara Rosso, Marta Guariglia, Angelo Armandi, Aurora Nicolosi, Gian Paolo Caviglia, Elisabetta Bugianesi
Summary: This study found that late chronotype and low adherence to the Mediterranean diet were associated with an increased risk of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
Article
Medicine, General & Internal
Flavia Vernin de Oliveira Terzi, Gabriel Cordeiro Camargo, Daniella Braz Parente, Ana Maria Pittella, Gilberto Silva-Junior, Gabrielle Goncalves de Novaes, Jaime Araujo Oliveira Neto, Julia Machado Barroso, Martha Valeria Tavares Pinheiro, Adriana Soares Xavier de Brito, Renee Sarmento de Oliveira, Rosana Souza Rodrigues, Renata de Mello Perez, Andrea Silvestre de Sousa, Renata Junqueira Moll-Bernardes
Summary: This study found an association between liver fibrosis and myocardial fibrosis in patients with NAFLD.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Yamei Duan, Xiongfeng Pan, Jiayou Luo, Xiang Xiao, Jingya Li, Prince L. Bestman, Miyang Luo
Summary: This study found a significant association between inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD). Increased concentrations of C-reactive protein (CRP), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and intercellular adhesion molecule-1 (ICAM-1) were significantly associated with increased risks of NAFLD.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Gastroenterology & Hepatology
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, with a prevalence of approximately 30%. Its prevalence varies depending on comorbidities and is expected to increase due to the rising obesity rates. NAFLD is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). This article provides a brief overview of NAFLD's definition and classification based on current knowledge.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong-Ho Lee, Ji-Hye Kim, Seung Up Kim
Summary: There is an association between metabolic dysfunction-associated fatty liver disease (MAFLD) or NAFLD and cardiovascular disease (CVD) risk, with MAFLD potentially being a better identifier for CVD risk than NAFLD. Fibrosis assessment can provide helpful prognostic information for subjects with MAFLD.
LIVER INTERNATIONAL
(2023)
Article
Nutrition & Dietetics
Kiyoung Lim, Minkyu Kang, Junggil Park
Summary: The study investigated the association between spontaneous fasting ketonuria and liver fibrosis in NAFLD patients without prediabetes and diabetes mellitus. Results showed that patients with ketonuria were younger, had lower levels of glucose and insulin resistance, and had an inverse association with liver fibrosis compared to patients without ketonuria. The presence of ketonuria in these patients may have favorable metabolic effects.
Article
Gastroenterology & Hepatology
Tracey G. Simon, Bjorn Roelstraete, Naim Alkhouri, Hannes Hagstrom, Johan Sundstrom, Jonas F. Ludvigsson
Summary: This study found that children and young adults with biopsy-proven NAFLD had significantly higher rates of incident MACE, including ischaemic heart disease and congestive heart failure, compared to matched population controls.
Article
Nutrition & Dietetics
Jun-Hyuk Lee, Yu-Jin Kwon, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Summary: This study found that metabolic score for IR (METS-IR) was inversely associated with ALF in patients with NAFLD, and its predictive ability for ALF was higher than that of triglyceride-glucose (TyG) index and homeostatic model assessment for IR (HOMA-IR).
Review
Medicine, General & Internal
Rafael Paternostro, Michael Trauner
Summary: Non-alcoholic fatty liver disease (NAFLD) is a liver disease with various pathologies. In addition to lifestyle changes and a few specific medications, there are new treatment options being studied. Treating complications of end-stage liver disease caused by non-alcoholic steatohepatitis (NASH) is important for the treatment of the complete clinical spectrum of NAFLD.
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Thaninee Prasoppokakorn, Wah-Kheong Chan, Vincent Wai-Sun Wong, Panyavee Pitisuttithum, Sanjiv Mahadeva, Nik Raihan Nik Mustapha, Grace Lai-Hung Wong, Howard Ho-Wai Leung, Pimsiri Sripongpun, Sombat Treeprasertsuk
Summary: This study validated the superiority of the FIB-8 score in predicting significant fibrosis in NAFLD patients in an Asian population compared to the NFS and FIB-4 score. The study suggests that a simple fibrosis score comprising commonly accessible basic laboratories may be beneficial for an initial assessment in primary care units and aiding in patient selection for further hepatologist referral.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Jung Gil Park, Jinho Jung, Kritin K. Verma, Min Kyu Kang, Egbert Madamba, Scarlett Lopez, Aed Qas Yonan, Amy Liu, Ricki Bettencourt, Claude Sirlin, Rohit Loomba
Summary: This study investigated the association between liver stiffness determined by MRE and the risk of cardiovascular disease in NAFLD patients. The results showed that liver stiffness is an independent predictor for the presence of CAC in NAFLD patients, suggesting that MRE can help identify patients in need of further cardiovascular risk assessment.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Immunology
Bader Alabdulaali, Fatema Al-rashed, Mohammed Al-Onaizi, Anwar Kandari, Joanna Razafiarison, Dorothy Tonui, Michayla R. Williams, Camille Bleriot, Rasheed Ahmad, Fawaz Alzaid
Summary: The liver is responsible for metabolizing and detoxifying blood, and consists of different cell types, including macrophages. These macrophages can be either resident Kupffer cells or differentiated from circulating monocytes. They play a role in maintaining liver homeostasis and can also contribute to disease progression. In non-alcoholic fatty liver disease (NAFLD), abnormal function of these macrophages leads to the development of liver conditions. Targeting these macrophages has become a potential therapeutic strategy for NAFLD.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Ilkay S. Idilman, Hsien Min Low, Tolga Gidener, Kenneth Philbrick, Taofic Mounajjed, Jiahui Li, AlMa M. Allen, Meng Yin, Sudhakar K. Venkatesh
Summary: The MRI-determined VAT can be utilized for predicting the presence of HS, NASH, and HF in patients with known or suspected NAFLD. VAT showed moderate correlation with liver PDFF and weak correlation with Lvol, Svol, and pancreas PDFF. The cut-off VAT volumes for predicting HS, NASH, and HF were calculated.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pediatrics
Antonella Mosca, Luca Della Volpe, Anna Alisi, Silvio Veraldi, Paola Francalanci, Giuseppe Maggiore
Summary: The study showed that Hepamet and APRI perform better than NFS and FIB-4 in identifying fibrosis in NAFLD patients. However, their positive predictive values are not high enough to be considered diagnostic, indicating the need for further research on new markers for fibrosis.
FRONTIERS IN PEDIATRICS
(2022)
Review
Immunology
Martina Maurelli, Paolo Gisondi, Giampiero Girolomoni
Summary: Comorbidities play a significant role in tailoring a personalized biological treatment for patients with moderate-to-severe psoriasis. Factors such as disease severity, patient demographics, and treatment goals need to be considered for optimal treatment outcomes. Personalized treatment aims to achieve maximum efficacy while minimizing the risk of adverse effects.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Review
Rheumatology
Kristina Callis Duffin, Luis Daniel Mazzuoccolo, Maria Julia Cura, Maria Esposito, Anthony P. Fernandez, Paolo Gisondi, Alessandro Giunta, Tom Hillary, Stefano Piaserico, James A. Solomon, Joseph F. Merola
Summary: This study aimed to summarize and evaluate the current evidence on the efficacy of therapies for cutaneous psoriasis in patients with psoriatic arthritis. The findings suggest that several pharmacologic therapeutic classes have high-quality evidence demonstrating efficacy for cutaneous psoriasis in the psoriatic arthritis population.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Dermatology
Ulrich Mrowietz, Jonathan Barker, Curdin Conrad, Denis Jullien, Paolo Gisondi, Andrea Flower, Jyotsna Reddy, Maria Paris, Hernan Picard, Shauna Jardon, Matthias Augustin
Summary: This study evaluated the efficacy and safety of apremilast in patients with plaque psoriasis in special areas and found that it significantly improved patients' quality of life, affected skin condition, and reduced itching and skin discomfort/pain.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Sophia Quirke-McFarlane, John Weinman, Emma S. Cook, Zenas Z. N. Yiu, Nick Dand, Sinead M. Langan, Katie Bechman, Teresa Tsakok, Kayleigh J. Mason, Helen McAteer, Freya Meynell, Bolaji Coker, Alexandra Vincent, Dominic Urmston, Amber Vesty, Jade Kelly, Camille Lancelot, Lucy Moorhead, Ines A. Barbosa, Herve Bachelez, Francesca Capon, Claudia R. Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jo Lambert, Luigi Naldi, Lluis Puig, Phyllis Spuls, Tiago Torres, Richard B. Warren, Hoseah Waweru, James B. Galloway, Christopher E. M. Griffiths, Jonathan N. Barker, Sam Norton, Catherine H. Smith, Satveer K. Mahil
Summary: This study investigated the nonadherence to immune-modifying therapy in individuals with psoriasis during the COVID-19 pandemic and its association with mental health. The most common reason for nonadherence was concerns about immunity. After adjusting for potential confounders, the association between anxiety and nonadherence to immune-modifying therapy became weaker and no longer significant. This study highlights the importance of clear and adequate communication with patients during a pandemic.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Review
Dermatology
Paolo Gisondi, David Simon, Ivette Alarcon, Effie Pournara, Lluis Puig
Summary: The purpose of this literature review is to examine the impact of IMID treatments on the immunogenicity of SARS-CoV-2 vaccination. The results show that patients receiving secukinumab treatment for IMIDs have an adequate immune response to SARS-CoV-2 vaccines, and there is no evidence of impaired immune function.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Biochemistry & Molecular Biology
Chiara Mareso, Elena Albion, William Cozza, Benedetta Tanzi, Stefano Cecchin, Paolo Gisondi, Sandro Michelini, Francesco Bellinato, Serena Michelini, Silvia Michelini, Matteo Bertelli, Giuseppe Marceddu
Summary: In this study, the whole sequence of FLG exon 3 was obtained using PacBio technology to investigate its association with skin diseases. A 2-step long-range PCR protocol was optimized to generate 13-kb amplicons covering the entire FLG exon 3 sequence. The PrimeSTAR protocol was found to be suitable for generating amplicons, and sequencing them may aid in identifying causative variants of the patients' disorders.
MOLECULAR BIOLOGY REPORTS
(2023)
Editorial Material
Dermatology
Laura Gnesotto, Guido Mioso, Federico Bardazzi, Federica Filippi, Vito Di Lernia, Alberto Motolese, Sergio Di Nuzzo, Andrea Conti, Federica Arginelli, Monica Corazza, Giulia Odorici, Alessandro Borghi, Paolo Gisondi, Luigi Naldi, Paolo Dapavo, Aurora Parodi, Martina Burlando, Stefano Piaserico
ACTA DERMATO-VENEREOLOGICA
(2023)
Article
Medicine, Research & Experimental
Claudia Giofre, Gabriella Fabbrocini, Concetta Potenza, Rossana Tiberio, Paolo Gisondi, Claudio Marasca, Carmen M. A. Nuzzo, Emiliana Benincasa, Luca Bianchi
Summary: This study investigated the real-world use and patient satisfaction with apremilast for plaque psoriasis in Italy. The results showed that apremilast can improve patients' quality of life and symptoms, and it is considered a valuable treatment option for moderate plaque psoriasis.
ADVANCES IN THERAPY
(2023)
Article
Rheumatology
Alen Zabotti, Gabriele De Marco, Laure Gossec, Xenofon Baraliakos, Daniel Aletaha, Annamaria Iagnocco, Paolo Gisondi, Peter Balint, Heidi Bertheussen, Wolf-Henning Boehncke, Nemanja S. Damjanov, Maarten de Wit, Enzo Errichetti, Helena Marzo-Ortega, Mikhail Protopopov, Lluis Puig, Ruben Queiro, Piero Ruscitti, Laura Savage, Georg Schett, Stefan Siebert, Tanja A. Stamm, Paul Studenic, Ilaria Tinazzi, Filip E. Van den Bosch, Annette van der Helm-van Mil, Abdulla Watad, Josef S. Smolen, Dennis G. McGonagle
Summary: This study proposes EULAR guidelines for the early diagnosis of psoriatic arthritis (PsA) by conducting research on multiple patients. It also establishes standardized operating procedures for clinical practice and trials, providing guidance and consensus in the field of prevention and interception of PsA for psoriasis patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Medicine, General & Internal
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, Paolo Dapavo, Gabriella Fabbrocini, Paolo Gisondi, Giuseppe Micali, Anna Maria Offidani, Giovanni Pellacani, Nevena Skroza, Rosa Giuseppa Angileri, Martina Burlando, Anna Campanati, Carlo Giovanni Carrera, Andrea Chiricozzi, Andrea Conti, Clara De Simone, Vito Di Lernia, Enzo Errichetti, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Matteo Megna, Maria Letizia Musumeci, Francesca Prignano, Antonio Giovanni Richetta, Emanuele Trovato, Marina Venturini, Ketty Peris, Piergiacomo Calzavara Pinton
Summary: A Delphi consensus document was developed to establish agreement on the use of brodalumab in the treatment of moderate-to-severe psoriasis. Consensus was reached on the key indications for the use of brodalumab based on the opinions of a panel of Italian dermatologists.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Francesco Bellinato, Paolo Gisondi, Angelo Valerio Marzano, Stefano Piaserico, Clara De Simone, Giovanni Damiani, Giuseppe Argenziano, Marina Venturini, Paolo Dapavo, Antonio Costanzo, Matteo Megna, Francesca Prignano, Martina Burlando, Francesca Satolli, Andrea Carugno, Elena Pezzolo, Marco Romanelli, Aldo Cuccia, Giampiero Girolomoni
Summary: This study investigated the clinical characteristics of patients experiencing a flare of generalized pustular psoriasis (GPP). The results showed that GPP flares can be severe and cause significant pain and itch, with a significant impact on quality of life. About one-third of patients may experience a persistent course of the flare and, with complications, require hospitalization.
Review
Immunology
Martina Maurelli, Paolo Gisondi, Giampiero Girolomoni
Summary: Advanced glycation end products (AGEs) are biologically active compounds that react with proteins to generate reactive aldehydes. They accumulate in tissues during ageing and in various metabolic and inflammatory disorders such as type 2 diabetes, obesity, cardiovascular diseases, chronic renal insufficiency, and psoriasis. The interaction of AGEs with their receptors (RAGEs) leads to cellular signaling, oxidative stress, and activation of inflammatory mediators. AGEs may play a pathogenic role in the intersection of inflammatory and metabolic diseases and could be a potential target for therapeutic strategies.
Article
Economics
Paolo Angelo Cortesi, Carla Fornari, Paolo Gisondi, Florenzo Iannone, Ippazio Cosimo Antonazzo, Elisabetta Aloisi, Martina Fiocchi, Daniela Ritrovato, Lorenzo Giovanni Mantovani
Summary: This study assessed the budget impact of introducing secukinumab in the Italian market. The results showed that secukinumab could reduce costs, especially in patients with psoriatic arthritis. For patients with non-radiographic axial spondyloarthritis, the use of secukinumab had no significant impact on the budget.
PHARMACOECONOMICS-OPEN
(2023)
Article
Medicine, General & Internal
Martina Maurelli, Paolo Gisondi, Francesco Bellinato, Alessandro Mantovani, Giovanni Targher, Giampiero Girolomoni
Summary: This study investigated the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with moderate-to-severe atopic dermatitis (AD), and found that the prevalence of NAFLD in AD patients was comparable to that in patients with a previous diagnosis of in situ melanoma. The results suggest that the Th2-type inflammation characteristic of AD is not a risk factor for NAFLD. Therefore, it is recommended to screen patients with moderate-to-severe psoriasis, but not those with AD, for NAFLD and other metabolic comorbidities.
JOURNAL OF CLINICAL MEDICINE
(2023)
Correction
Dermatology
Francesco Bellinato, Paolo Gisondi, Emilio Filippucci, Francesca Tozzi, Angelo Fassio, Giovanni Adami, Luca Idolazzi
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)
